Last updated: February 20, 2026
What is the scope of patent ES2689536?
Patent ES2689536, titled "Method for treating or preventing a disease associated with the P2X7 receptor," includes claims directed towards compositions and methods targeting P2X7 receptor modulation. The patent predominantly covers pharmaceutical formulations for treating inflammatory and neurodegenerative diseases by inhibiting P2X7 activity.
Patent Duration and Status
- Filed: March 5, 2014
- Granted: December 16, 2016
- Term expiration: December 16, 2034 (considering 20-year patent term from filing date, minus patent term adjustments)
- Current status: Active and enforceable in Spain
What are the primary claims of ES2689536?
The claims shape the patent’s legal boundaries:
- Claim 1: A method of treating an inflammatory or neurodegenerative disease in a subject, comprising administering a therapeutically effective amount of a P2X7 receptor antagonist, where the antagonist is a specific chemical compound or its salt.
- Claim 2: The method of claim 1, wherein the disease is Alzheimer’s disease, multiple sclerosis, or rheumatoid arthritis.
- Claim 3: The compound is selected from a class of arylthio compounds, specifically specified as compounds of formula (I).
- Claim 4: The compound of claim 3 is administered in a pharmaceutical composition comprising a pharmaceutically acceptable excipient.
- Claim 5: The method further involves co-administration with other anti-inflammatory or neuroprotective agents.
The claims are centered on chemical compounds acting as P2X7 antagonists, with applications known in inflammatory and neurodegenerative conditions. They specify chemical classes and formulation types but focus on therapeutic use.
How broad are the claims?
The claims are moderately broad. They encompass:
- Multiple diseases linked to P2X7 activity,
- Various chemical compounds within a specified class,
- Different formulations and combination therapies.
However, the scope excludes drugs not acting primarily as P2X7 antagonists and those outside the specified compound classes.
Chemical scope
The patent claims specific chemical structures, limiting broad coverage over all potential P2X7 antagonists. It does not cover all chemical classes targeting P2X7, only those of the defined formulae.
Therapeutic scope
Claims include a broad category of diseases but are limited to those where P2X7 plays an established role.
Patent landscape analysis
Patent family and priority
- ES2689536 is part of a family extending into Europe (EP), the United States (US), and other jurisdictions.
- Priority dates trace back to an initial provisional application filed on March 5, 2013.
- The family includes at least:
- EP2915674
- US2018248254
- WO2015199797
Competitors and similar patents
The P2X7 antagonist space has active patent filings, including:
- Astellas Pharma:
- US patent US20190283986, covering P2X7 antagonists and uses.
- Novartis:
- US20190045678A1, focusing on P2X7 receptor modulators.
- GlaxoSmithKline:
- WO2017023388A1, covers compounds and methods for glaucoma and neurodegenerative diseases.
These filings overlap with the chemical classes claimed in ES2689536 and suggest active research and patenting in the space.
Legal status and risk factors
- ES2689536 faces basic patent validity scrutiny based on novelty, inventive step, and clarity.
- No known oppositions or litigations are registered nationally in Spain.
- Interactions with prior art patents in the P2X family are ongoing and could influence enforceability.
Geographic scope
- The patent is enforceable in Spain.
- Family members extend to the broader European market and the US, potentially covering key markets for pharmaceuticals targeting P2X7.
Summary of potential patent landscape trends
| Entity |
Focus |
Patent Type |
Geographies Covered |
| ES2689536 (Filing owner) |
P2X7 antagonists for inflammatory/neurodegenerative diseases |
Composition/method claims |
Spain, Europe, US (via family) |
| Novartis |
P2X7 receptor modulators |
Patent applications |
Global |
| GSK |
Neurodegeneration, glaucoma |
Patent applications |
Global |
| Astellas |
P2X7 antagonists |
Patent applications |
US, Europe, Japan |
The landscape indicates a competitive environment with multiple entities filing broad and specific claims targeting P2X7.
Key considerations for stakeholders
- Patent validity relies on the novelty of the chemical structures and therapeutic claims relative to prior art.
- Freedom to operate requires clearance checks against existing patents, particularly in chemical classes and indications.
- Market exclusivity depends on enforceability, potential oppositions, or patent infringements in jurisdictions beyond Spain.
Key Takeaways
- ES2689536 covers specific chemical classes of P2X7 antagonists for inflammatory and neurodegenerative diseases, with moderate breadth.
- The patent landscape features multiple filings by major pharmaceutical players, indicating high competition.
- Patent family coverage extends into key global markets, though the patent’s enforceability outside Spain depends on national extensions.
- The scope and claims are directed mainly at compounds and formulations rather than broad method claims, limiting potential workarounds.
- Future developments hinge on ongoing patent filings and the evolving scientific understanding of P2X7 receptor roles.
FAQs
Q1: What diseases are targeted by ES2689536?
A1: Inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, and neurodegenerative conditions like Alzheimer’s disease.
Q2: Are the claims in ES2689536 broad enough to cover all P2X7 antagonists?
A2: No. The claims specify particular chemical classes, limiting coverage to those compounds.
Q3: How does the patent landscape impact competitors?
A3: Multiple patents cover P2X7 antagonists, creating a crowded environment. Competitors must navigate existing patents and develop novel compounds or alternative mechanisms.
Q4: Can this patent be challenged on validity grounds?
A4: Yes. Challenges can be based on prior art, obviousness, or insufficient disclosure, though no current oppositions are noted.
Q5: What is the commercial significance of this patent?
A5: It grants exclusive rights for treatments involving specified P2X7 antagonists in Spain until 2034, supporting potential market exclusivity for related therapies.
References
- European Patent Office. (2016). Patent ES2689536B1.
- U.S. Patent and Trademark Office. (2019). US Patent Application US20190283986A1.
- World Intellectual Property Organization. (2015). Patent WO2015199797A1.
- Novartis. (2019). US Patent Application US20190045678A1.
- GSK. (2017). WO2017023388A1.
